ctDNA detection at baseline was associated with worse recurrence-free, overall survival in BRAF^V600-mutant stage III melanoma

Risk for brain metastases development increased in association with elevated plasma levels of S100B, higher metastatic stage

Royal blue backgrounds preferred for photographing darker skin, offering increased contrast without aberrant hues

In this recurring column, Dermsquared and J.P. Morgan provide tailored financial strategies and investment insights for the dermatology community. Each 500-word article highlights key...

Baricitinib efficacious for achieving holistic response across all three hair-bearing sites

Quality of images produced by autonomous TBP and dermoscopic device comparable to standard dermoscopic techniques

All lesions demonstrated improvement by week 24, with 42 percent achieving ≥80 percent repigmentation

Nonbrisk tumor-infiltrating lymphocytes denoted high risk and were present in 80 percent of progressing tumors

Factors include lower income, non-Hispanic White race, Medicaid/uninsured, greater distance to treatment centers

No evidence of different cardiovascular safety profiles seen for ustekinumab versus adalimumab, etanercept, secukinumab

Delgocitinib well tolerated and efficacious when used as needed in 36-week open-label trial

Risks for local recurrence, nodal metastases, distant metastases, disease-specific death increase as risk factor number increases

Significantly more patients receiving baricitinib 2 mg, 4 mg had SALT score ≤20, ≤10 versus placebo at week 36

Many patients who achieved clear skin with tapinarof treatment maintained low disease activity after treatment-free interval

Agency says 90 percent of tested products have undetectable or extremely low levels of benzene

Memorial Sloan Kettering Cancer Center and Melanoma Institute of Australia models are most frequently externally validated

Both treatment approaches demonstrate achievement, maintenance of improvement of more than 90 percent in Eczema Area and Severity Index

Remibrutinib results in significant improvement in composite measure of itching and hives at week 12 after second-generation H1-antihistamine treatment

In this recurring column, Dermsquared and J.P. Morgan provide tailored financial strategies and investment insights for the dermatology community. Each 500-word article highlights key...

Increased risks seen based on twin cohort and case-cotwin studies

Review finds red, blue, and combination wavelength devices are all effective

Amjetiva and Imradi as effective as Humira for new users and in switcher analysis